EA200800355A1 - Нейтрализующие антитела человека против b7rp1 - Google Patents

Нейтрализующие антитела человека против b7rp1

Info

Publication number
EA200800355A1
EA200800355A1 EA200800355A EA200800355A EA200800355A1 EA 200800355 A1 EA200800355 A1 EA 200800355A1 EA 200800355 A EA200800355 A EA 200800355A EA 200800355 A EA200800355 A EA 200800355A EA 200800355 A1 EA200800355 A1 EA 200800355A1
Authority
EA
Eurasian Patent Office
Prior art keywords
b7rp1
antibodies
antibodies against
human antibodies
neutralizing human
Prior art date
Application number
EA200800355A
Other languages
English (en)
Other versions
EA021669B1 (ru
Inventor
Джералд Сиу
Веньянь Шень
Стивен Кийоши Йошинага
Хайчунь Хуань
Original Assignee
Амджен Инк.
Медарекс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амджен Инк., Медарекс, Инк. filed Critical Амджен Инк.
Publication of EA200800355A1 publication Critical patent/EA200800355A1/ru
Publication of EA021669B1 publication Critical patent/EA021669B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В данном изобретении предложены антитела, которые взаимодействуют с человеческим В7-связанным белком-1 (B7RP1) или связываются с ним, и антитела, которые связываются с B7RP1 и посредством этого нейтрализуют его функцию. В изобретении также предложены фармацевтические композиции указанных антител и способы нейтрализации функции B7RP1 и, в частности, для лечения иммунных расстройств (например, неадекватного иммунного ответа) путем введения фармацевтически эффективного количества антител анти-В7RP1. Также предложены способы определения количества B7RP1 в образце с использованием антител против B7RP1.
EA200800355A 2005-07-18 2006-07-18 Нейтрализующие антитела человека против b7rp1 EA021669B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70026505P 2005-07-18 2005-07-18
PCT/US2006/027862 WO2007011941A2 (en) 2005-07-18 2006-07-18 Human anti-b7rp1 neutralizing antibodies

Publications (2)

Publication Number Publication Date
EA200800355A1 true EA200800355A1 (ru) 2008-08-29
EA021669B1 EA021669B1 (ru) 2015-08-31

Family

ID=37562100

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800355A EA021669B1 (ru) 2005-07-18 2006-07-18 Нейтрализующие антитела человека против b7rp1

Country Status (26)

Country Link
US (4) US7868140B2 (ru)
EP (7) EP2388277A3 (ru)
JP (1) JP5142998B2 (ru)
KR (4) KR20130023356A (ru)
CN (1) CN101321783B (ru)
AU (1) AU2006270009A1 (ru)
BR (1) BRPI0614040B8 (ru)
CA (2) CA2614972C (ru)
CR (1) CR9745A (ru)
DK (1) DK1915398T3 (ru)
EA (1) EA021669B1 (ru)
ES (1) ES2572177T3 (ru)
HK (1) HK1120049A1 (ru)
HR (1) HRP20160875T1 (ru)
HU (1) HUE028830T2 (ru)
IL (6) IL188642A (ru)
MX (1) MX2008000734A (ru)
NO (1) NO345593B1 (ru)
NZ (2) NZ625807A (ru)
PL (1) PL1915398T3 (ru)
RS (1) RS54984B1 (ru)
SG (2) SG196835A1 (ru)
SI (1) SI1915398T1 (ru)
UA (1) UA102667C2 (ru)
WO (1) WO2007011941A2 (ru)
ZA (1) ZA200801137B (ru)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2332976T1 (sl) * 1999-02-03 2014-08-29 Amgen Inc. Novi polipeptidi, vkljuäśeni v imunskem odgovoru
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
EP2388277A3 (en) * 2005-07-18 2013-03-20 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AU2008293425B2 (en) * 2007-08-31 2014-09-18 Amgen Inc. Solid-state protein formulation
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
WO2010064090A1 (en) * 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
AR074438A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
US8722046B2 (en) * 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
EA032537B1 (ru) 2010-06-07 2019-06-28 Эмджен Инк. Способ работы устройства для доставки лекарственного средства
EP3050899B1 (en) * 2010-09-27 2019-09-04 Janssen Biotech, Inc. Antibodies binding human collagen ii
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
WO2012135315A1 (en) 2011-03-31 2012-10-04 Amgen Inc. Vial adapter and system
LT2699293T (lt) 2011-04-20 2019-04-25 Amgen Inc. Automatinio purškimo prietaisas
EP3335747B1 (en) 2011-10-14 2021-04-07 Amgen Inc. Injector and method of assembly
EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
ES2780395T3 (es) 2012-11-21 2020-08-25 Amgen Inc Dispositivo de administración de fármacos
JOP20140087B1 (ar) * 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CN113559363B (zh) 2013-03-22 2023-10-31 美国安进公司 注射器及装配方法
CA2909923A1 (en) 2013-04-23 2014-10-30 The University Court Of The University Of Aberdeen Isolation of therapeutic target specific vnar domains to icosl
EP2992013B1 (en) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP7051293B2 (ja) 2013-10-24 2022-04-11 アムジエン・インコーポレーテツド 温度感知制御を伴う薬剤送達システム
US11097055B2 (en) 2013-10-24 2021-08-24 Amgen Inc. Injector and method of assembly
RU2019118984A (ru) 2014-01-10 2019-08-06 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
PT3126391T (pt) 2014-03-31 2019-11-27 Univ Hospital Of North Norway Anticorpos contra hpa-1a
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
KR102506249B1 (ko) 2014-06-03 2023-03-03 암겐 인코포레이티드 약물 전달 시스템 및 사용 방법
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
AU2015337858B2 (en) 2014-10-29 2020-09-24 Teva Pharmaceuticals Australia Pty Ltd. Interferon alpha2b variants
JP6716566B2 (ja) 2014-12-19 2020-07-01 アムジエン・インコーポレーテツド 近接センサ付き薬物送達装置
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
ES2748750T3 (es) 2015-02-17 2020-03-17 Amgen Inc Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP3721922B1 (en) 2016-03-15 2022-05-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
CN116942793A (zh) * 2016-09-19 2023-10-27 昂科医药 Cd80和cd86结合蛋白组合物及其用途
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
JP7064501B2 (ja) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
IL268478B2 (en) 2017-03-07 2023-10-01 Amgen Inc Inserting a needle using super pressure
JP2020509837A (ja) 2017-03-09 2020-04-02 アムジエン・インコーポレーテツド 薬剤送達装置のための挿入機構
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN110446512B (zh) 2017-03-28 2022-03-18 美国安进公司 柱塞杆和注射器组件系统以及方法
EP3634546A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Torque driven drug delivery device
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
CN111132711B (zh) 2017-10-06 2022-07-01 安进公司 带有联锁组件的药物递送装置及相关组装方法
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
CA3079665A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
MX2020005066A (es) 2017-11-16 2020-08-20 Amgen Inc Autoinyector con deteccion de detencion y punto final.
MA52186A (fr) 2018-03-26 2021-02-17 Amgen Inc Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
SG11202010100QA (en) 2018-04-12 2020-11-27 Amgen Inc Methods for making stable protein compositions
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US20210228815A1 (en) 2018-07-24 2021-07-29 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
AU2019350660A1 (en) 2018-09-28 2021-03-18 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AR116679A1 (es) 2018-10-02 2021-06-02 Amgen Inc Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
CA3109988A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
EP3873566A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020092056A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial needle retraction
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2021062372A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4229080A1 (en) 2020-10-15 2023-08-23 Amgen Inc. Relative unpaired glycans in antibody production methods
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US5151510A (en) * 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5625825A (en) * 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7435796B1 (en) * 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
SI2332976T1 (sl) * 1999-02-03 2014-08-29 Amgen Inc. Novi polipeptidi, vkljuäśeni v imunskem odgovoru
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
KR101222450B1 (ko) 1999-03-25 2013-01-16 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP2829609A1 (en) * 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
DE60035517T2 (de) * 1999-09-21 2008-03-20 Genetics Institute, LLC, Cambridge Gl50 moleküle, sowie verwendungen derselben
GB0016633D0 (en) 2000-07-07 2000-08-23 Bp Exploration Operating Process
JP4236925B2 (ja) * 2000-11-28 2009-03-11 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
WO2004106380A2 (en) 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
JPWO2006003999A1 (ja) * 2004-07-05 2008-07-31 財団法人化学及血清療法研究所 ヒト抗ヒトｂ７ｒｐ−１抗体およびその抗体フラグメント
EP2388277A3 (en) * 2005-07-18 2013-03-20 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EA021669B1 (ru) 2015-08-31
RS54984B1 (sr) 2016-11-30
DK1915398T3 (en) 2016-07-04
CA2614972A1 (en) 2007-01-25
US20130171695A1 (en) 2013-07-04
EP2397499A2 (en) 2011-12-21
KR101024758B1 (ko) 2011-03-24
JP5142998B2 (ja) 2013-02-13
KR20130023356A (ko) 2013-03-07
HRP20160875T1 (hr) 2016-09-23
IL218888A0 (en) 2012-05-31
KR20100101016A (ko) 2010-09-15
WO2007011941A3 (en) 2007-05-03
BRPI0614040B8 (pt) 2021-05-25
HUE028830T2 (en) 2017-01-30
EP2388277A3 (en) 2013-03-20
SG196835A1 (en) 2014-02-13
EP2397496A3 (en) 2013-05-29
CN101321783B (zh) 2015-08-26
UA102667C2 (ru) 2013-08-12
KR101263079B1 (ko) 2013-05-09
EP2397499A3 (en) 2013-12-25
EP1915398B1 (en) 2016-04-20
BRPI0614040A2 (pt) 2011-03-09
US20110104757A1 (en) 2011-05-05
KR20140097582A (ko) 2014-08-06
NO20080302L (no) 2008-04-15
JP2009501549A (ja) 2009-01-22
US8981071B2 (en) 2015-03-17
KR20080049014A (ko) 2008-06-03
EP2388276A2 (en) 2011-11-23
WO2007011941A9 (en) 2008-02-21
NZ625807A (en) 2015-11-27
ZA200801137B (en) 2010-05-26
EP2397497A3 (en) 2013-11-27
CA2614972C (en) 2014-08-19
IL218892A0 (en) 2012-05-31
EP2397496A2 (en) 2011-12-21
CA2854576A1 (en) 2007-01-25
US20160145345A1 (en) 2016-05-26
NO345593B1 (no) 2021-05-03
IL188642A0 (en) 2008-04-13
EP2397498A3 (en) 2013-11-27
CR9745A (es) 2008-07-22
EP2388276A3 (en) 2013-11-27
MX2008000734A (es) 2008-03-19
US20080166352A1 (en) 2008-07-10
BRPI0614040B1 (pt) 2020-02-04
SG164369A1 (en) 2010-09-29
EP2397497A2 (en) 2011-12-21
AU2006270009A1 (en) 2007-01-25
CN101321783A (zh) 2008-12-10
IL218889A0 (en) 2012-05-31
IL188642A (en) 2015-01-29
HK1120049A1 (zh) 2009-03-20
EP2397498A2 (en) 2011-12-21
WO2007011941A2 (en) 2007-01-25
EP1915398A2 (en) 2008-04-30
IL218893A0 (en) 2012-05-31
ES2572177T3 (es) 2016-05-30
IL218890A0 (en) 2012-05-31
US9266945B2 (en) 2016-02-23
EP2388277A2 (en) 2011-11-23
US10072090B2 (en) 2018-09-11
US7868140B2 (en) 2011-01-11
SI1915398T1 (sl) 2016-07-29
NZ604090A (en) 2014-07-25
PL1915398T3 (pl) 2016-10-31

Similar Documents

Publication Publication Date Title
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
EA201100694A1 (ru) Антитело к cd38 человека и его применение
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA200600254A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
EA200800812A1 (ru) Композиции антитела против cd3
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201190018A1 (ru) Миостатинсвязывающие белки
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA201070596A1 (ru) Гуманизированные антитела против tl1a
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
WO2008105886A3 (en) HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
EA201170716A1 (ru) Антитела к с-мет
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
MA38161A1 (fr) Anticorps anti-bmp-6
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title